SOPHiA GENETICS (SOPH) Competitors

$4.74 +0.23 (+5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$4.72 -0.02 (-0.32%)

As of 04:04 PM Eastern

SOPH vs. IMCR, WVE, AVBP, ABCL, and MBX

Should you buy SOPHiA GENETICS stock or one of its competitors? MarketBeat compares SOPHiA GENETICS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SOPHiA GENETICS include Immunocore (IMCR), WAVE Life Sciences (WVE), ArriVent BioPharma (AVBP), AbCellera Biologics (ABCL), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.

How does SOPHiA GENETICS compare to Immunocore?

Immunocore (NASDAQ:IMCR) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Immunocore currently has a consensus target price of $57.75, indicating a potential upside of 100.80%. SOPHiA GENETICS has a consensus target price of $7.50, indicating a potential upside of 58.23%. Given Immunocore's stronger consensus rating and higher probable upside, equities analysts clearly believe Immunocore is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

84.5% of Immunocore shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 10.4% of Immunocore shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immunocore has a net margin of -6.68% compared to SOPHiA GENETICS's net margin of -44.48%. Immunocore's return on equity of -7.07% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Immunocore has higher revenue and earnings than SOPHiA GENETICS. Immunocore is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.64	-$35.51M	-$0.55	N/A
SOPHiA GENETICS	$77.27M	4.20	-$79M	-$0.52	N/A

In the previous week, Immunocore had 16 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 20 mentions for Immunocore and 4 mentions for SOPHiA GENETICS. Immunocore's average media sentiment score of 0.88 beat SOPHiA GENETICS's score of 0.37 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immunocore beats SOPHiA GENETICS on 13 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to WAVE Life Sciences?

SOPHiA GENETICS (NASDAQ:SOPH) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SOPHiA GENETICS currently has a consensus price target of $7.50, indicating a potential upside of 58.23%. WAVE Life Sciences has a consensus price target of $27.50, indicating a potential upside of 298.55%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

SOPHiA GENETICS has higher revenue and earnings than WAVE Life Sciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.20	-$79M	-$0.52	N/A
WAVE Life Sciences	$71.80M	18.49	-$204.38M	-$1.06	N/A

SOPHiA GENETICS has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

SOPHiA GENETICS has a net margin of -44.48% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

In the previous week, SOPHiA GENETICS had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for SOPHiA GENETICS and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.69 beat SOPHiA GENETICS's score of 0.37 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, ArriVent BioPharma had 5 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 9 mentions for ArriVent BioPharma and 4 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.37 beat ArriVent BioPharma's score of -0.33 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

SOPHiA GENETICS has higher revenue and earnings than ArriVent BioPharma. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
SOPHiA GENETICS	$77.27M	4.20	-$79M	-$0.52	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ArriVent BioPharma presently has a consensus price target of $42.78, suggesting a potential upside of 50.52%. SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 58.23%. Given SOPHiA GENETICS's higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

ArriVent BioPharma has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. ArriVent BioPharma's return on equity of -48.98% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Summary

ArriVent BioPharma beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to AbCellera Biologics?

SOPHiA GENETICS (NASDAQ:SOPH) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

SOPHiA GENETICS has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.20	-$79M	-$0.52	N/A
AbCellera Biologics	$79.21M	16.96	-$146.41M	-$0.48	N/A

SOPHiA GENETICS has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

SOPHiA GENETICS currently has a consensus price target of $7.50, suggesting a potential upside of 58.23%. AbCellera Biologics has a consensus price target of $8.17, suggesting a potential upside of 85.61%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

SOPHiA GENETICS has a net margin of -44.48% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, AbCellera Biologics had 5 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 9 mentions for AbCellera Biologics and 4 mentions for SOPHiA GENETICS. AbCellera Biologics' average media sentiment score of 0.72 beat SOPHiA GENETICS's score of 0.37 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats SOPHiA GENETICS on 14 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to MBX Biosciences?

SOPHiA GENETICS (NASDAQ:SOPH) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

In the previous week, MBX Biosciences had 26 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 30 mentions for MBX Biosciences and 4 mentions for SOPHiA GENETICS. MBX Biosciences' average media sentiment score of 0.78 beat SOPHiA GENETICS's score of 0.37 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. MBX Biosciences' return on equity of -24.52% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
MBX Biosciences	N/A	-24.52%	-23.59%

SOPHiA GENETICS currently has a consensus price target of $7.50, suggesting a potential upside of 58.23%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 70.31%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

SOPHiA GENETICS has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.20	-$79M	-$0.52	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

SOPHiA GENETICS has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MBX Biosciences beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOPH vs. The Competition

Export

Metric	SOPHiA GENETICS	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$324.64M	$1.41B	$6.29B	$12.46B
Dividend Yield	N/A	N/A	2.79%	5.30%
P/E Ratio	-9.12	64.00	20.87	25.61
Price / Sales	4.20	6.20	521.62	63.45
Price / Cash	N/A	23.25	42.94	55.34
Price / Book	7.07	5.20	9.86	6.71
Net Income	-$79M	-$54.76M	$3.55B	$333.77M
7 Day Performance	-12.22%	-3.94%	-0.26%	0.40%
1 Month Performance	-4.44%	4.48%	1.39%	4.03%
1 Year Performance	54.40%	-5.10%	41.07%	36.33%

SOPHiA GENETICS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOPH SOPHiA GENETICS	2.4487 of 5 stars	$4.74 +5.1%	$7.50 +58.2%	+44.6%	$324.64M	$77.27M	N/A	520
IMCR Immunocore	3.7873 of 5 stars	$28.84 +1.1%	$60.89 +111.1%	+1.4%	$1.45B	$400.02M	N/A	320	Analyst Revision
WVE WAVE Life Sciences	2.7611 of 5 stars	$7.18 -3.9%	$27.50 +283.0%	+9.4%	$1.44B	$42.73M	N/A	240
AVBP ArriVent BioPharma	2.5598 of 5 stars	$29.83 -1.8%	$43.00 +44.2%	+51.5%	$1.41B	N/A	N/A	40	Earnings Report Analyst Forecast Analyst Revision
ABCL AbCellera Biologics	3.3089 of 5 stars	$4.66 +1.5%	$8.17 +75.3%	+127.1%	$1.40B	$75.13M	N/A	500	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. IMCR, WVE, AVBP, ABCL, and MBX

How does SOPHiA GENETICS compare to Immunocore?

Summary

How does SOPHiA GENETICS compare to WAVE Life Sciences?

Summary

How does SOPHiA GENETICS compare to ArriVent BioPharma?

Summary

How does SOPHiA GENETICS compare to AbCellera Biologics?

Summary

How does SOPHiA GENETICS compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. IMCR, WVE, AVBP, ABCL, and MBX

How does SOPHiA GENETICS compare to Immunocore?

Do analysts prefer IMCR or SOPH?

Which has more volatility & risk, IMCR or SOPH?

Do institutionals & insiders believe in IMCR or SOPH?

Is IMCR or SOPH more profitable?

Which has higher valuation & earnings, IMCR or SOPH?

Does the media prefer IMCR or SOPH?

Summary

How does SOPHiA GENETICS compare to WAVE Life Sciences?

Do institutionals and insiders have more ownership in SOPH or WVE?

Do analysts rate SOPH or WVE?

Which has better earnings & valuation, SOPH or WVE?

Which has more volatility & risk, SOPH or WVE?

Is SOPH or WVE more profitable?

Does the media favor SOPH or WVE?

Summary

How does SOPHiA GENETICS compare to ArriVent BioPharma?

Does the media refer more to AVBP or SOPH?

Which has more volatility & risk, AVBP or SOPH?

Which has stronger earnings & valuation, AVBP or SOPH?

Do insiders & institutionals have more ownership in AVBP or SOPH?

Do analysts prefer AVBP or SOPH?

Is AVBP or SOPH more profitable?

Summary

How does SOPHiA GENETICS compare to AbCellera Biologics?

Which has better valuation and earnings, SOPH or ABCL?

Which has more volatility & risk, SOPH or ABCL?

Do analysts recommend SOPH or ABCL?

Is SOPH or ABCL more profitable?

Does the media favor SOPH or ABCL?

Do insiders and institutionals hold more shares of SOPH or ABCL?

Summary

How does SOPHiA GENETICS compare to MBX Biosciences?

Does the media favor SOPH or MBX?

Is SOPH or MBX more profitable?

Do analysts recommend SOPH or MBX?

Which has stronger earnings and valuation, SOPH or MBX?

Which has more volatility and risk, SOPH or MBX?

Do institutionals and insiders hold more shares of SOPH or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools